Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.

doi:10.1016/j.jhep.2016.02.044

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.

Journal of hepatology - 1 Jul 2016

Desnoyer Aude, Pospai Dan, Lê Minh Patrick, Gervais Anne, Heurgué-Berlot Alexandra, Laradi Achour, Harent Stanislas, Pinto Adriana, Salmon Dominique, Hillaire Sophie, Fontaine Hélène, Zucman David, Simonpoli Anne-Marie, Muret Patrice, Larrouy Lucile, Bernard Chabert Brigitte, Descamps Diane, Yazdanpanah Yazdan, Peytavin Gilles

Abstract excerpt

BACKGROUND & AIMS: Hepatitis C virus (HCV) infection is an independent risk factor for chronic kidney disease and leads to faster liver disease progression in patients requiring hemodialysis than in those with normal renal function. Little is known about the use of a sofosbuvir-containing regimen for infected patients on hemodialysis. We aimed to describe the pharmacokinetics, safety and efficacy of sofosbuvir in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Renal Dialysis

Share to Ribavirin

Share to Simeprevir

Share to Sofosbuvir

Source

Open in PubMed

Identifiers

PMID: 26952005
DOI: 10.1016/j.jhep.2016.02.044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.PMID 26952005Read ↗

Sofosbuvir-Based HCV Treatment in Maintenance Hemodialysis Patients: A Single-Center Study.Semantic proximity Read ↗

Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.Semantic proximity Read ↗

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.Semantic proximity Read ↗

Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis.Semantic proximity Read ↗

Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.Semantic proximity Read ↗

Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.Semantic proximity Read ↗

Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.Semantic proximity Read ↗

COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.